Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Declines By 99.4%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 26,461 shares, a decline of 99.4% from the July 30th total of 4,613,535 shares. Based on an average daily volume of 2,740,460 shares, the days-to-cover ratio is presently 0.0 days. Approximately 5.8% of the shares of the company are sold short.

Wall Street Analyst Weigh In

SXTC has been the topic of several research reports. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday. Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Down 5.8%

Shares of NASDAQ SXTC traded down $0.22 during trading hours on Tuesday, reaching $3.58. 172,732 shares of the stock were exchanged, compared to its average volume of 399,954. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76. China SXT Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $83,758.80. The stock’s fifty day simple moving average is $102.70 and its 200 day simple moving average is $137.58.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings results on Wednesday, July 1st. The company reported ($5.60) earnings per share for the quarter. The company had revenue of $0.26 million during the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in shares of China SXT Pharmaceuticals in the fourth quarter valued at about $36,000. Virtu Financial LLC increased its position in China SXT Pharmaceuticals by 107.5% during the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after acquiring an additional 15,013 shares during the period. Finally, Citadel Advisors LLC bought a new position in China SXT Pharmaceuticals during the third quarter worth about $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.